by Patrick Baert
A researcher in a lab coat in Beijing holds up the hopes of humanity in his fingers: “Coronavac”, an experimental vaccine against the coronavirus that has upended the world.
Sinovac Biotech, which is conducting one of the four clinical trials that have been authorised in China, has claimed great progress in its research and promising results among monkeys.
While human trials have just started, the company says it is ready to make 100 million doses per year to combat the virus, which surfaced in central China late last year before spreading across the globe and killing more than 220,000 people.
Thousands of shots of the vaccine, which is based on an inactivated pathogen, have already been produced and packaged in a white and orange case emblazoned with the name “Coronavac”.
While the drug has a long way to go before it is approved, the company must show that it can produce it on a large scale and submit batches to be controlled by the authorities.
The World Health Organization has warned that developing a vaccine could take 12 to 18 months, and Sinovac does not know when its half-millilitre injection will be ready for the market.
“It’s the question everyone is asking themselves,” Sinovac director of brand management Liu Peicheng told AFP.
Nasdaq-listed Sinovac has experience in mass-producing a drug against a global virus: it was the first pharmaceutical company to market a vaccine against H1N1, or swine flu, in 2009.
More than 100 labs around the world are scrambling to come up with a vaccine, but only seven — including Sinovac — are currently in clinical trials, according to the London School of Hygiene and Tropical Medicine.
Sinovac has published results showing that its vaccine has “largely protected” macaques from infection in an animal trial.
It’s findings have yet to be peer reviewed by the global scientific community.

Volunteers abroad

The company has since conducted human trials, administering the serum on 144 volunteers in April in eastern Jiangsu province.
Sinovac, which has some 1,000 employees, hopes to see results on the safety of its product by the end of June following the first two phases of clinical trials.
The firm will then move to phase three of the trials, which will determine whether the vaccine is effective among carriers of the virus.
But Sinovac is facing a problem for phase three. There are too few cases of infections in China nowadays to have enough volunteers for the decisive tests.
The country has largely brought the coronavirus under control after imposing an unprecedented lockdown on the central city of Wuhan and its surrounding Hubei province.
Only around 600 people remain hospitalised in the country and few new cases are reported every day.
This means that Sinovac may have to look for human guinea pigs abroad.
“Currently we are talking to several countries in Europe and in Asia,” said Meng Weining, Sinovac’s director for international affairs.
Typically several thousand people would be needed for phase three, but “it’s not easy to get these numbers in any country,” Meng said.

‘Day and night’

Even with success in the next stages, Sinovac would not be able to produce enough vaccines to treat the entire world population.
But Meng said the company is ready to collaborate with foreign partners which already buy its other vaccines against the flu and hepatitis.
As it continues its research, the company is getting ready for mass production.
Sinovac is building a production facility in the south of the capital that should be up and running by the end of the year.
“We work day and night, we have three shift working groups, for 24 hours, so that means we don’t waste any minute for the vaccine development,” Meng said.
– AFP

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

回乡马国公民新措施 明日起无需批准信通行证

马来西亚首相宣布将步入修复式行管令,6月10日起自外国回乡的国民不必再向马国使馆或马国高级专员公署申请批准信或通行证了。 马国首相于周日(6月7日)宣布,将从明天起开始实施修复式行管令(PKPP)至8月31日。马国外交部配合有关调整,于今天在脸书帖文,指自外国回乡的国人无需再向相关当局申请批准信或通行证。 当局也表示,回乡的马国人可以改为在居家强制隔离,无需呆在隔离中心。该国国防部长依斯迈沙比利日前曾指出,明日起返回国家的人们,都必须在机场进行病毒拭子测试,结果呈阴性反应人士可在家中进行强制隔离。 回乡的人们在接受测试后,必须下载手机追踪应用程序(My Sejahtera)及戴上隔离手环,以方便当局跟进他们的行踪。

NZ PM Jacinda Ardern instructs military to tighten border controls following lapse involving COVID-19-positive persons leaving quarantine

by Neil SANDS New Zealand Prime Minister Jacinda Ardern ordered the military…

新保集团和IHiS被罚100万元 二职员被炒 总裁等高层仅被罚款

个人资料保护委员会,于今日宣布重罚综合保健信息系统公司(IHiS)和新保集团,共被罚款100万元,必须在30天内付清。这也是该委会迄今为止罚金额最高的罚款。 IHiS因未采取足够安全措施保护病患个人资料,而遭罚款75万元。 新保集团则因负责人员对事故反应程序不熟悉、太过依赖IHiS公司,被罚25万元。 佘林发:黄瑞莲等高层愿受罚款处分 至于新保集团董事会主席佘林发则表示,该集团领导层,包括总裁黄瑞莲都自愿接受被罚款。 他指出,病患的安全和数据隐私理应是该集团的首要考量,对于事故担起责任,并对受影响病患道歉。 不过,他并未透露新保集团高层的罚款金额。 根据个资保护委会的文告,去年发生的新保集团网袭事件历来最严重,导致约150万名病人的个人资料被盗,还有约16万人的门诊配药记录被泄露,当中包括总理李显龙与数名部长的记录。事件爆发后,该委会也收到许多民间投诉。 IHiS二职员被开除 IHiS的一名技术主管,以及一名保安事故应变经理将被开除。该公司称有关经理已多次接获职员通报,却没采取有效行动,两名职员的主管也被罚款。 公司的五名高级管理人员包括总裁连水木,需承担集体责任,并支付显著的罚款额。 一名负责该系统的集群信息安全官,因没有遵守通报程序将被降职。

Resident pressured at her doorstep to buy six durians for $385

A Facebook post about a durian scam posted by Eugene Lau has…